Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-25
2006-07-25
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S018000
Reexamination Certificate
active
07081463
ABSTRACT:
The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formulawherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.
REFERENCES:
patent: 3238216 (1966-03-01), Janssen
patent: 3839340 (1974-10-01), Scharpf
patent: 4329353 (1982-05-01), Stokbroekx et al.
patent: 5739336 (1998-04-01), Weinhardt et al.
patent: 6043366 (2000-03-01), Adam et al.
patent: 6060482 (2000-05-01), Heine et al.
patent: 6071925 (2000-06-01), Adam et al.
patent: 6113527 (2000-09-01), Adam et al.
patent: 6262066 (2001-07-01), Tulshian et al.
patent: 6277991 (2001-08-01), Hohlweg et al.
patent: 6777421 (2004-08-01), Jordan et al.
patent: 2003/0109539 (2003-06-01), Jordan et al.
patent: 921125 (1999-06-01), None
patent: 0997464 (2000-03-01), None
patent: 997464 (2000-05-01), None
patent: 2000-169476 (2000-06-01), None
patent: WO 93/12789 (1993-07-01), None
patent: WO 95/07294 (1995-03-01), None
patent: 99/59997 (1999-11-01), None
patent: WO 99/59997 (1999-11-01), None
patent: WO 00/06545 (2000-02-01), None
patent: WO 01/07050 (2001-02-01), None
patent: WO 01/36418 (2001-05-01), None
patent: WO 01/39723 (2001-06-01), None
patent: WO 01 46192 (2001-06-01), None
patent: WO 01/96337 (2001-06-01), None
patent: WO 03/010168 (2001-07-01), None
patent: WO 01/94346 (2001-12-01), None
patent: WO 02/83673 (2002-10-01), None
patent: WO 02/085355 (2002-10-01), None
PCT Search Report dated Feb. 18, 2004 for PCT APPLN. No. PCT/US03/27956.
Calo, G. et al., “Pharmacological Profile of Nociceptin/Orphanin FQ Receptors” Clinical and Experimental Pharmacology and Physiology (2002), 29, 223-228.
Chalon, S. et al “Iodoethylspiperone, a New Potential Agent for Exploration of Central Dopamine D2Receptors: Synthesis and PreliminaryIn VivoStudy” Nucl. Med. Bio. (1990), 17(4), 389-395.
Kiesewetter, D. et al., “Syntheses and D2Receptor Affinities of Derivatives of Spiperone Containing Aliphatic Halogens” Appl. Radiat. Isot. (1986), 37(12), 1181-1188.
Poulain, R. et al., “From Hit to Lead. Analyzing Structure—Profile Relationship” J.Med. Chem. (2001), 44, 3391-3401.
Poulain, R. et al., “From Hit to Lead. Combining Two Complementary Methods for Focused Library Design. Application to μ Opiate Ligands” J. Med. Chem. (2001), 44, 3378-3390.
Röver S. et al., “High-Affinity, Non-Peptide Agonists for the ORL1 (Orphanin FQ/Nociceptin) Receptor” J. Med. Chem. (2000), 43, 1329-1338.
Satyamurthy, N. et al., “3-(2′[18F]Fluoroethyl)spiperone, a Potent Dopamine Antagonist: Synthesis, Structural Analysis andIn-vivoUtilization in Humans” Appl. Radiat. Isot. (1990) 41(2), 113-129.
U.S. Appl. No. 10/909,858, Ortho-McNeil Pharmaceutical, Inc.
Ronzoni, Silvano et al., “Lead generation and lead optimization approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists,” Exp. Opin. Ther. Patents, 2001, (11)4, pp. 525-546.
Zaverl, Nurulain, “Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: Research tools and potential therapeutic agents,” Life Sciences 73 (2003), pp. 663-678.
Jenck, Francois et al., “A synthetic agonist at the orphanin FQ
ociceptin receptor ORL1: Anxiolytic profile in the rat,” PNAS, Apr. 25, 2000, vol. 97, No. 9, pp. 4938-4953.
Thomsen, Chrisian et al., “(8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]-dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist,” British Journal of Pharmacology (2000) 131, 903-908.
Battista Kathleen
Bignan Gilles
Connolly Peter J.
Middleton Steven A.
Orsini Michael
Desai Rita
Janssen Pharmaceutica N.V.
Woodrow Hal B.
LandOfFree
Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3560829